Genelux Corp (GNLX) Stock Price, Quote & News

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and e...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 267 9889

Website: www.genelux.com

Address:

2625 Townsgate Road, Suite 230, Westlake Village, United States

Kupper Mar. 30 at 7:29 PM

$GNLX this is getting rediculously cheap.

0 · Reply

KC1391 Mar. 30 at 1:46 PM

$GNLX is this a buy again now? Buy low sell high

0 · Reply

Shawnkick007 Mar. 25 at 2:05 PM

$GNLX I swear when this thing gets back up to $40 I’m selling this turd.

1 · Reply

anachartanalyst Mar. 20 at 5:02 PM

$GNLX https://anachart.com/wp-content/uploads/ana_temp/1774026109_soc-img.jpg

0 · Reply

Kupper Mar. 3 at 6:45 PM

$GNLX why the drop in share price today?

1 · Reply

BillionerOfKing Mar. 2 at 7:14 PM

$GNLX Current Stock Price: $2.91 Contracts to trade: $5.0 GNLX Mar 20 2026 Call Entry: $0.05 Exit: $0.06 ROI: 31% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

PortfolioOverture Feb. 20 at 2:13 PM

$GNLX Genelux develops oncolytic virus therapies. Clinical milestones are the primary catalyst. Early-stage risk remains high.

0 · Reply

OfficialStocktwitsUser Feb. 12 at 10:32 PM

$GNLX RSI: 32.73, MACD: -0.3002 Vol: 0.19, MA20: 2.66, MA50: 3.47 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BounceRaider Feb. 10 at 1:05 PM

$GNLX is a biotech (Genelux) focused on oncolytic viruses; clinical development is high-risk and capital intensive.

0 · Reply

05ford Feb. 5 at 4:41 AM

$GNLX boy this thing needs a good shot in the arm.

0 · Reply

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Jan 12, 2026, 4:00 PM EST - 2 months ago

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

Jan 8, 2026, 9:13 AM EST - 3 months ago

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

Jan 7, 2026, 4:01 PM EST - 3 months ago

Genelux Corporation Announces Proposed Public Offering of Common Stock

Jan 2, 2026, 8:00 AM EST - 3 months ago

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Nov 5, 2025, 4:20 PM EST - 5 months ago

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Aug 7, 2025, 4:20 PM EDT - 8 months ago

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Jul 7, 2025, 7:00 AM EDT - 9 months ago

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

May 6, 2025, 4:10 PM EDT - 11 months ago

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

Mar 28, 2025, 4:10 PM EDT - 1 year ago

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 25, 2025, 8:31 AM EDT - 1 year ago

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Feb 3, 2025, 6:45 AM EST - 1 year ago

Genelux Corporation Announces New Chief Financial Officer

Dec 13, 2024, 7:01 AM EST - 1 year ago

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Nov 6, 2024, 4:01 PM EST - 1 year ago

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 31, 2024, 10:59 AM EDT - 1 year ago

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Oct 22, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Oct 9, 2024, 4:15 PM EDT - 1 year ago

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

May 24, 2024, 8:00 AM EDT - 2 years ago

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

May 23, 2024, 4:01 PM EDT - 2 years ago

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

May 9, 2024, 4:25 PM EDT - 2 years ago

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

$Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer$

Nov 27, 2023, 7:00 AM EST - 2 years ago

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Nov 14, 2023, 5:50 PM EST - 2 years ago

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Sep 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 30, 2023, 1:56 PM EDT - 2 years ago

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Aug 2, 2023, 4:00 PM EDT - 2 years ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Jul 20, 2023, 4:45 PM EDT - 2 years ago

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Jul 11, 2023, 4:12 AM EDT - 2 years ago

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Jul 10, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Jun 29, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Jun 22, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Jun 12, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces $18 Million Private Placement

$Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On$

May 25, 2023, 4:01 PM EDT - 3 years ago

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

May 15, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces $33 Million Private Placement

Mar 26, 2023, 10:50 PM EDT - 3 years ago

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

Mar 23, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Jan 26, 2023, 6:40 AM EST - 3 years ago

Genelux IPO prices at bottom of range

Jan 25, 2023, 9:00 PM EST - 3 years ago

Genelux Corporation Announces Pricing of Initial Public Offering

Sep 19, 2022, 1:49 PM EDT - 3 years ago

IPO Update: Genelux Finalizes $16 Million IPO Plan

Sep 19, 2022, 9:08 AM EDT - 3 years ago

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

Kupper Mar. 30 at 7:29 PM

$GNLX this is getting rediculously cheap.

0 · Reply

KC1391 Mar. 30 at 1:46 PM

$GNLX is this a buy again now? Buy low sell high

0 · Reply

Shawnkick007 Mar. 25 at 2:05 PM

$GNLX I swear when this thing gets back up to $40 I’m selling this turd.

1 · Reply

anachartanalyst Mar. 20 at 5:02 PM

$GNLX https://anachart.com/wp-content/uploads/ana_temp/1774026109_soc-img.jpg

0 · Reply

Kupper Mar. 3 at 6:45 PM

$GNLX why the drop in share price today?

1 · Reply

BillionerOfKing Mar. 2 at 7:14 PM

0 · Reply

PortfolioOverture Feb. 20 at 2:13 PM

$GNLX Genelux develops oncolytic virus therapies. Clinical milestones are the primary catalyst. Early-stage risk remains high.

0 · Reply

OfficialStocktwitsUser Feb. 12 at 10:32 PM

0 · Reply

BounceRaider Feb. 10 at 1:05 PM

$GNLX is a biotech (Genelux) focused on oncolytic viruses; clinical development is high-risk and capital intensive.

0 · Reply

05ford Feb. 5 at 4:41 AM

$GNLX boy this thing needs a good shot in the arm.

0 · Reply

PLATINUM_TRADES Jan. 16 at 8:04 PM

$GNLX $3.00 Possible on this break of resistance we have another overnight swing winner... Keep it going🚨🚨

0 · Reply

BillionerOfKing Jan. 15 at 11:26 AM

$GNLX Current Stock Price: $2.61 Contracts to trade: $2.5 GNLX Jan 16 2026 Call Entry: $2.34 Exit: $4.10 ROI: 75% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

garygb Jan. 11 at 2:44 PM

$GNLX Holding and adding.My guess is it's bottomed out.

0 · Reply

PaulThomasTPG Jan. 9 at 2:22 AM

$FNMA $BBAI Its feels like forever ago, that these were trading as penny stocks! $GNLX running all the way to 250% in 11months, and then plummeting 80% in a month is pretty WILD! https://www.youtube.com/watch?v=8ed505uoqpk

0 · Reply

CSkaugrud Jan. 8 at 5:02 PM

$GNLX

0 · Reply

DARKP00L Jan. 8 at 4:46 PM

$GNLX 11:46 on Jan. 08 2026 Genelux shares are trading lower. The company announced the pricing of a public offering of 6.67 million common shares at a price of $3.00 per share. #tradeideas

0 · Reply

DARKP00L Jan. 8 at 2:22 PM

$GNLX 09:15 on Jan. 08 2026 Genelux Prices ~$20M Public Offering Of 6.67M Shares At A Price Of $3/Share #tradeideas

0 · Reply

OpenOutcrier Jan. 8 at 2:08 PM

$GNLX (-10.6% pre) Genelux stock falls after announcing proposed public offering https://ooc.bz/l/89068

0 · Reply

AmaraNic Jan. 7 at 9:08 PM

$GNLX I’m so disappointed in this one.

0 · Reply

Market Cap	115.15M
Revenue (ttm)	10,000.00
Net Income (ttm)	-32.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-321,500.02%
Debt to Equity Ratio	0.00

Volume	138,300
Avg Vol	187,868
Day's Range	N/A - N/A
Shares Out	44.81M
Stochastic %K	68%
Beta	0.47
Analysts	Strong Sell
Price Target	$17.17